Vpriv available for Type 1 Gaucher disease - ONA
Links shared publicly online about this topic.
- 1,346total visits
Vpriv available for Type 1 Gaucher disease - ONA
View full resource at oncologynurseadvisor.com
Tags: Lipid Storage Disease, Gaucher Disease, Disease and Condition, FDA, Shire, disease
Most Recently Shared on March 1, 2010 at 4:13 pm By:
Vpriv available for Type 1 Gaucher disease http://goo.gl/fb/3kQb
Shire's Replagal, VPRIV new data against Fabry, Gaucher disease presented at ACMG meeting
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, presented new data for Replagal in patients with Fabry disease, and VPRIV in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.” View full resource at news-medical.net
Most Recently Shared on March 22, 2011 at 9:55 am By:
Shire's Replagal, VPRIV new data against Fabry, Gaucher disease presented at ACMG meeting: Shire plc, the global... http://bit.ly/hW92OA
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on December 1, 2010 at 12:14 pm By:
Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease: Shire plc, the global specia... http://bit.ly/eXIaXq
Shire receives approval for VPRIV to treat type 1 Gaucher disease
news-medical.net — “Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.” View full resource at news-medical.net
Most Recently Shared on August 27, 2010 at 10:15 am By:
Shire receives approval for VPRIV to treat type 1 Gaucher disease: Shire, the global specialty biopharmaceutical c... http://bit.ly/d0YvUf
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy o” View full resource at news-medical.net
Most Recently Shared on July 2, 2010 at 11:52 am By:
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients: Shire... http://bit.ly/dbtzNQ
Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease
medicalnewstoday.com — “Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human ce” View full resource at medicalnewstoday.com
Most Recently Shared on May 29, 2010 at 1:06 pm By:
Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease http://mnt.to/3Dhn
OnePath Gaucher Application available for patients with Type 1 Gaucher disease
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.” View full resource at news-medical.net
Most Recently Shared on May 24, 2010 at 2:12 pm By:
OnePath Gaucher Application available for patients with Type 1 Gaucher disease: Shire plc, the global specialty bi... http://bit.ly/9enDrk
Shire Presents Positive Data For Patients With Type 1 Gaucher Disease Who Switched To VPRIV(TM)
healthcare.tweetmeme.com — “All the news on healthcare” View full resource at healthcare.tweetmeme.com
Most Recently Shared on March 27, 2010 at 2:23 pm By:
Healthcare TweetMeme Health Social Media
Shire Presents Positive Data For Patients With Type 1 Gaucher Disease Who Swi.. http://retwt.me/1MEM3 (via @lstmjournals)
Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV
buzzup.com — “Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.” View full resource at buzzup.com
Most Recently Shared on March 26, 2010 at 11:39 am By:
Genetics News: Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who swit... http://buzzup.com/rnye
Advertisement
